Kine Science

KineScience is a clinical-stage biotechnology company headquartered in Seoul, South Korea, specializing in the development of novel small molecule inhibitors for inflammatory and autoimmune disorders. The company's core technology, the Kine-Link platform, enables the design of highly selective modulators of cytokine signaling pathways, specifically targeting Janus kinases like JAK1 and TYK2. Their lead clinical asset, KS-101, is currently undergoing evaluation for atopic dermatitis, aiming to provide a superior oral alternative to current standards of care. With a robust pipeline targeting rheumatoid arthritis and other immune-mediated conditions, KineScience is positioned to address significant unmet needs in the global immunology market.